NNC 26-9100

NNC 26-9100
Identifiers
	IUPAC name 1-[3-[(5-bromo-2-pyridinyl)-[(3,4-dichlorophenyl)methyl]amino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea;
CAS Number	199522-35-5;
PubChem CID	9893924;
UNII	9X9D329ZX2;
Chemical and physical data
Formula	C22H25BrCl2N6S
Molar mass	556.35 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=C(C=C1CN(CCCNC(=S)NCCCC2=CN=CN2)C3=NC=C(C=C3)Br)Cl)Cl;
	InChI InChI=1S/C22H25BrCl2N6S/c23-17-5-7-21(29-12-17)31(14-16-4-6-19(24)20(25)11-16)10-2-9-28-22(32)27-8-1-3-18-13-26-15-30-18/h4-7,11-13,15H,1-3,8-10,14H2,(H,26,30)(H2,27,28,32); Key:UREJDUPKGMFJRU-UHFFFAOYSA-N;

NNC 26-9100 is a chemical compound which acts as an agonist at somatostatin receptor 4. It has been researched for potential applications in the treatment of Alzheimer's disease, and has positive effects on learning and memory in animal studies.^[1]^[2]^[3]^[4]

References

↑ Liu S, Crider AM, Tang C, Ho B, Ankersen M, Stidsen CE (April 1999). "2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity". Current Pharmaceutical Design. 5 (4): 255–263. doi:10.2174/1381612805666230109213422. PMID 10101224.
↑ Sandoval KE, Farr SA, Banks WA, Niehoff ML, Morley JE, Crider AM, et al. (March 2011). "Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice". European Journal of Pharmacology. 654 (1): 53–59. doi:10.1016/j.ejphar.2010.12.013. PMC 3026075. PMID 21185826.
↑ Sandoval K, Umbaugh D, House A, Crider A, Witt K (November 2019). "Somatostatin Receptor Subtype-4 Regulates mRNA Expression of Amyloid-Beta Degrading Enzymes and Microglia Mediators of Phagocytosis in Brains of 3xTg-AD Mice". Neurochemical Research. 44 (11): 2670–2680. doi:10.1007/s11064-019-02890-6. PMC 6894394. PMID 31630317.
↑ Schober J, Polina J, Walters F, Scott N, Lodholz E, Crider A, et al. (2021). "NNC 26-9100 increases Aβ1-42 phagocytosis, inhibits nitric oxide production and decreases calcium in BV2 microglia cells". PLOS ONE. 16 (7) e0254242. doi:10.1371/journal.pone.0254242. PMC 8266108. PMID 34237100.

[1] Liu S, Crider AM, Tang C, Ho B, Ankersen M, Stidsen CE (April 1999). "2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity". Current Pharmaceutical Design. 5 (4): 255–263. doi:10.2174/1381612805666230109213422. PMID 10101224.

[2] Sandoval KE, Farr SA, Banks WA, Niehoff ML, Morley JE, Crider AM, et al. (March 2011). "Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice". European Journal of Pharmacology. 654 (1): 53–59. doi:10.1016/j.ejphar.2010.12.013. PMC 3026075. PMID 21185826.

[3] Sandoval K, Umbaugh D, House A, Crider A, Witt K (November 2019). "Somatostatin Receptor Subtype-4 Regulates mRNA Expression of Amyloid-Beta Degrading Enzymes and Microglia Mediators of Phagocytosis in Brains of 3xTg-AD Mice". Neurochemical Research. 44 (11): 2670–2680. doi:10.1007/s11064-019-02890-6. PMC 6894394. PMID 31630317.

[4] Schober J, Polina J, Walters F, Scott N, Lodholz E, Crider A, et al. (2021). "NNC 26-9100 increases Aβ1-42 phagocytosis, inhibits nitric oxide production and decreases calcium in BV2 microglia cells". PLOS ONE. 16 (7) e0254242. doi:10.1371/journal.pone.0254242. PMC 8266108. PMID 34237100.

[1]

[2]

[3]

[4]

See also

References